(Reuters) -Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade. Bristol will pick up Mirati's portfolio drugs that target the genetic drivers of specific cancers including its lung cancer drug, Krazati, which was approved in December. A second compound - MRTX1719 - which could be used in some types of lung cancer was also attractive to the company, Bristol executives said in an interview.
Embattled British bank Metro
announced a 325 million pound capital
raise and 600 million pound debt refinancing on Sunday, after a
weekend of urgent talks to secure its future after a volatile
week.
Embattled British bank Metro
announced a 325 million pound capital
raise and 600 million pound debt refinancing on Sunday, after a
weekend of urgent talks to bolster its balance sheet after.
Embattled Metro Bank secures capital, Colombian billionaire Gilinski to take control wkzo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkzo.com Daily Mail and Mail on Sunday newspapers.